

QUARTERLY REPORT – Extract from the official Swedish report

1 January – 30 September 2016
(NGM: LIFE B)


Financial information

Group

- Net sales for the period January – September 2016 totals 5 623 kSEK
- Profit after taxes totals – 13 847 kSEK.
- Profit per share was – 0,01 kr.

Parent company

- Net sales for the period January – September 2016 totaled 5 623 kSEK (3 455 kSEK for the same period previous year).
- Profit after taxes totals – 11 978 kSEK (- 11 314 kSEK for the same period previous year).
- Profit per share was – 0,01 SEK (- 0,05 SEK for the same period previous year).



The blood analysis company LifeAssays® AB's business concept is to meet doctors and patients need for simple and reliable test for rapid bedside blood analysis. The company's patented products consist of self-developed instruments and disposable reagent which is harmless to patients, staff and the environment. Alternative markets for the company's products are used in veterinary medicine as well as food and pharmaceutical industries.

CEO comments

Third quarter 2016

- Net sales for the Group as well as for the parent during the quarter was 1 645 kSEK which is an increase by 74%% over the third quarter in 2015.
- Increase in number of tests sold by 26% over the third quarter 2015.
- During 2016, China has passed Korea and become or largest market in Asia. The use per instrument is increasing and we believe our potential in China is similar to the potential of the Japanese market.
- New distributors added in Germany and in Italy.
- The project with our unique quantitative disposable test is progressing in line with our plan. The integration of electronics and reagent has started.
- The recruitment to the cancer study, ongoing during 2015/2016, started to reach the end during the third quarter. A total of approximately 200 dogs are included and a summary of data will be completed during the remainder of 2016. The study has attracted attention in the US through the press and TV.
- Expenses has increased compared to the same period last year, mainly driven by the consolidation of Magnasense Oy along with intensified activity with in marketing and sales.

25th of november 2016

Anders Ingvarsson, MSc

VD för LifeAssays AB

anders.ingvarsson@lifeassays.com

Share information & owner structure

The share price (last transaction) for the quarter was 0,038 (0,05) SEK, which gives a market cap of 62,9 (20,1) mSEK. The nominal value is 0,02 kr.

The average number of shares for the period was 1 045 901 062 shares.

Largest owners 30th of September 2016	No of shars	Votes/capital
Tibia Konsult AB	148 194 934	8,95%
Biothom Oy	108 795 785	6,57%
Avanza Pension	108 463 475	6,55%
Nordnet Pensionsförsäkring AB	44 707 988	2,70%
Matz Eklund	51 382 260	3,10%
Peter Schlein-Andersen	47 850 000	2,89%
Bo Göran Åkerlund	40 000 000	2,41%
Svenska Handelsbanken Markets	38 608 722	2,33%
Christian Borgvall	20 500 000	1,24%
AN Holding	18 000 000	1,09%
Others (4 603 st)	1 029 840 070	62,18%
Total	1 656 343 234	100,00%

Outstanding warrants

There are currently 482 970 502 warrants outstanding. Each warrant entitles to subscription of one share at 70% of the volume weighted average price during the 20 days succeeding the release of the Q4 report for 2016. In the event of the Company not having released the Q4 report the calculation period shall start on the 27th of February 2017. The minimum price is set at the nominal value, 0,02 SEK and the maximum price is set at 0,06 SEK. A full redemption of the warrants will increase the share capital by 9 659 kSEK.

Financial calendar

Q3 report 2016	Friday 25 th of November 2016
Q4 report 2016	Thursday 16 th February 2017
Annual report 2016	April 2017

Contact information:

LifeAssays® AB, Scheelevägen 19F:2, 223 70 LUND, tel +46 46-286 5400, fax +46 46-286 5419
Web: www.lifeassays.com, epost: info@lifeassays.com

For further information contact CEO of LifeAssays AB, Anders Ingvarsson, telephone +46 46-286 54 00 or email: info@lifeassays.com

Condensed statement of comprehensive income - Gruop

TSEK	2016	2015	2016	2015	2015
	Jul-Sept	Jul-Sept	Jan-Sept	Jan-Sept	Jan-Dec
Net sales					
Net sales	1 645	942	5 623	3 455	4 755
Other income	26	8	80	26	30
Total net sales	1 671	950	5 703	3 481	4 785
Operating expenses					
Raw materials and consumables	-680	-521	-2 481	-1 905	-2 624
Other external expenses	-2 055	-1 758	-6 836	-5 006	-8 664
Personnel expenses	-2 727	-2 064	-8 922	-7 433	-10 225
Depreciation and writedowns of intangible and tangible assets	-390	-165	-1 160	-477	-656
Other operating income/cost					-83
Total operating expenses	-5 852	-4 508	-19 399	-14 821	-22 252
Operating profit/loss	-4 181	-3 558	-13 696	-11 340	-17 467
Profit /loss from financial activities					
Interest income	57	1	91	27	15
Interest expenses	-34	-6	-259	-1	-30
Profit before taxes	-4 158	-3 563	-13 864	-11 314	-17 482
Taxes	-8	0	17		-10
Profit/loss for the period	-4 166	-3 563	-13 847	-11 314	-17 492
TSEK	2016	2015	2016	2015	2015
	Jul-Sept	Jul-Sept	Jan-Sept	Jan-Sept	Jan-Dec
Profit/loss for the period	-4 166	-3 563	-13 847	-11 314	-17 492
Items that may be reclassified to the income statement:					
Translation differences	21	-	26	-	-62
Total comprehensive income for the period	-4 145	-3 563	-13 821	-11 314	-17 554
Key ratios:					
Earnings per share before and after dilution	-0,003	-0,01	-0,013	-0,05	-0,06
Average number of shares	1 631 269 069	401 622 040	1 045 901 062	234 264 284	284 617 096
Number of shares at the end of the period	1 656 343 234	402 658 286	1 656 343 234	402 658 286	402 658 286
Key ratios - Group	2 016	2015	2 016	2015	2015
	Jul-Sept	Jul-Sept	Jan-Sept	Jan-Sept	Jan-Dec
Equity/asset ratio (%)	60%	89%	60%	89%	51%
Return on equity	neg	neg	neg	neg	neg
Profit/loss after finance net (TSEK)	-4 158	-3 563	-13 864	-11 314	-17 482
Profit/loss per share (sek/share)	-0,003	-0,01	-0,01	-0,05	-0,06
Cash flow (TSEK)	-67	-3 663	7 646	2 203	-3 536

Condensed consolidated balance sheet - Group

TSEK	2016-09-30	2015-09-30	2015-12-31
Assets			
Fixed assets			
Intangible fixed assets	18 752	2 612	17 334
Tangible assets	478	208	240
Financial fixed assets			
Total fixed assets	19 230	2 820	17 574
Current assets			
Inventories	1 986	2 081	2 124
Other current assets	3 150	2 209	2 269
Liquid assets, including current investments	13 331	11 403	5 659
Total current assets	18 467	15 693	10 052
Total assets	37 697	18 513	27 626
Liabilities and shareholders equity			
Share capital	33 127	20 133	20 133
Other capital contributed	127 895	6 457	131 911
Reserves	85		-62
Profit/Loss brought forward	-124 479	1 152	-120 355
Total comprehensive income for the period	-13 847	-11 314	-17 492
Total equity	22 781	16 428	14 135
Long term liabilities			
Interest bearing liabilities	9 774		8 566
Deferred tax liabilities	2 036		1 948
Total long-term liabilities	11 810	0	10 514
Current liabilities			
Other current liabilities	3 106	2 085	2 977
Total current liabilities	3 106	2 085	2 977
Total liabilities and shareholders equity	37 697	18 513	27 626

Consolidated changes in shareholders equity

TSEK	Share capital	Ongoing share issue	Other capital contributed	Reserves	Profit/loss brought forward	Profit/loss for the year	Shareholders equity
Opening balance	20 133	4 016	127 895	-62	-120 354	-17 492	14 136
Disposition of previous years' result					-17 492	17 492	0
Ongoing share issue	4 016	-4 016					0
Reduction of share capital	-14 489				14 489		0
Share issue	19 319				-1023		18 296
Redemption of warrants	4 148				-99		4 049
Translation difference group companies				147			147
Profit/loss for the year						-13 847	-13 847
Closing balance	33 127	0	127 895	85	-124 479	-13 847	22 781

Consolidated Cash flow statement - Group

TSEK	2016	2015	2016	2015	2015
	Jul-Sept	Jul-Sept	Jan-Sept	Jan-Sept	Jan-Dec
Operating activities					
Operating profit/loss	-4 181	-3 563	-13 696	-11 340	-17 467
Interest received	57	1	99	27	15
Interest paid	-34	-6	-259	-1	-30
Other items not included in cash flow	270	170	1 240	477	679
Cash flow from operating activities before changes in working capital	-3 888	-3 398	-12 616	-10 837	-16 803
Change in operating receivables	-302	-186	138	-291	-334
Change in inventory	359	761	-852	-16	-132
Change in operating liabilities	-444	-659	56	-306	329
Cash flow from operating activities	-4 275	-3 482	-13 274	-11 450	-16 940
Investment activities					
Intangible assets	-21	-129	-1 673	-323	-616
Fixed assets	1	0	-314	-29	-52
Investment in net assets in group companies				0	46
Total cash flow from investment activities	-20	-129	-1 987	-352	-622
Financing activities					
New share issue	4 049	-52	22 345	14 005	14 026
Change in financial receivables	179		562		
Cash flow from financing activities	4 228	-52	22 907	14 005	14 026
Cash flow for the period	-67	-3 663	7 646	2 203	-3 536
Liquid assets at the beginning of the period	13 377	15 066	5 659	9 200	9 200
Exchange rate difference liquid assets	21	-	26	-	-5
Cash flow for the period	-67	-3 663	7 646	2 203	-3 536
Liquid assets at the end of the period	13 331	11 403	13 331	11 403	5 659

Segment information

Split of Net sales per product group	2016	2015	2016	2015	2015
	July-Sept	July-Sept	Jan-Sept	Jan-Sept	Jan-Dec
Tester	1451	870	4865	2 790	3760
Instrument	82	66	413	391	618
Övrigt	112	7	345	274	377
Total	1 645	943	5 623	3 333	4 755

Net sales per region (Split based on where the customers are established)	2016	2015	2016	2015	2015
	July-Sept	July-Sept	Jan-Sept	Jan-Sept	Jan-Dec
Sweden	792	46	2 425	625	804
Other Nordic	438	587	1 305	1 462	1 961
Other Europé	100	33	275	183	286
North America	6	0	19	194	214
Asia	309	277	1 599	991	1 490
Total	1 645	943	5 623	3 333	4755